ReviewCancer control : journal of the Moffitt Cancer Center
The Role of CXCL11 and its Receptors in Cancer: Prospective but Challenging Clinical Targets.
Review in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 12 citations in OpenAlex.
- Vascular Endothelial Growth Factor Receptor 2 (VEGFR2/KDR) Promotes KSHV Lytic Replication and Drives Pro-Inflammatory Cytokine Release and Cancer Signaling.Journal of medical virology · 2026Article
- Article
- Cytokines and cancer-associated fibroblasts.Journal of hematology & oncology · 2026Review
- Dual-chemokine-armed oncolytic Senecavirus A co-recruits cDC1 and CXCR3Journal for immunotherapy of cancer · 2026Article
- Sex-biased plasma inflammatory protein profile in obesity.Scientific reports · 2026Article
- Systems biology approaches to unravelling neonatal sepsis and potential for precision diagnostics and therapeutics.Frontiers in pharmacology · 2026Review
- Two-sample Mendelian randomization analysis of 91 circulating inflammatory protein levels and meningioma.Medicine · 2025Article
- CXCL9 is a dual‑role biomarker in colorectal cancer linked to mitophagy and modulated by ALKBH5.Molecular medicine reports · 2025Article
- CRISPR/Cas9-mediated Knockout ofCancer genomics & proteomics · 2025Article
- Low CXCL11 expression is indicative of poor prognosis in rectal cancer patients undergoing preoperative chemoradiotherapy: a retrospective cohort study.Virchows Archiv : an international journal of pathology · 2025Article
- Transcriptional and microbial profile of gastric cancer patients infected with Epstein-Barr virus.Frontiers in oncology · 2025Article
- CXCL11: A Novel Biomarker in Colorectal Cancer as Metastasis Predictor.OncoTargets and therapy · 2025Article
- Overlapping genes connect rheumatoid arthritis and head and neck cancer: coincidence or shared immune pathophysiology?Frontiers in medicine · 2025Article
- Chemokines: humble yet mighty players in the tumour microenvironment.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemokine ligand 11 is a member of the CXC chemokine family and exerts its biological function mainly through binding to CXCR3 and CXCR7. The
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.